Skip to main content
Log in

Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding

  • Therapy in Practice
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Pediatric patients often have poor pregnancy outcomes. Systemic lupus erythematosus predominantly impacts women in their second to fourth decade of life, with childhood-onset disease being particularly aggressive. Reproductive issues are an important clinical consideration for pediatric patients with systemic lupus erythematosus (SLE), as maintaining good disease control and planning a pregnancy are important for maternal and fetal outcomes. In this clinical review, we will consider the safety of medications in managing childhood-onset SLE during conception, pregnancy, and breastfeeding. The developing fetus is at highest risk for teratogenicity from maternal medications during the period of critical organogenesis, which occurs between the first 3–8 weeks following conception. Medications known to be teratogenic, leading to a specific pattern of malformations, include mycophenolic acid, methotrexate, and cyclophosphamide. These should be discontinued prior to a planned pregnancy or as soon as pregnancy is suspected. Hydroxychloroquine is safe and should be continued throughout pregnancy and breastfeeding in those without contraindications to it. Azathioprine and calcineurin inhibitors are felt to be compatible with pregnancy in usual doses and may be used prior to and throughout pregnancy and lactation. Non-fluorinated corticosteroids including methylprednisolone and prednisone are inactivated by the placenta and can be used if needed for maternal indication during gestation. Addition of aspirin may be considered around the 12th week of gestation for prevention of pre-eclampsia. Illustrative cases are presented that demonstrate management of adolescents with childhood-onset SLE through conception, pregnancy, and breastfeeding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mina R, Brunner HI. Pediatric lupus: are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am. 2010;36(1):53–80, vii–viii.

    PubMed  Google Scholar 

  2. Tucker LB, Uribe AG, Fernandez M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case–control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Malabarey OT, Balayla J, Klam SL, Shrim A, Abenhaim HA. Pregnancies in young adolescent mothers: a population-based study on 37 million births. J Pediatr Adolesc Gynecol. 2012;25(2):98–102.

    PubMed  Google Scholar 

  4. Chen XK, Wen SW, Fleming N, Demissie K, Rhoads GG, Walker M. Teenage pregnancy and adverse birth outcomes: a large population based retrospective cohort study. Int J Epidemiol. 2007;36(2):368–73.

    CAS  PubMed  Google Scholar 

  5. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374(9):843–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol. 2003;30(10):2127–32.

    PubMed  Google Scholar 

  7. United States National Library of Medicine. ToxNet: Toxicology Data Network. LACTMED. https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm. Updated August 4, 2018. Accessed 8 Aug 2018.

  8. Ulug P, Oner G, Kasap B, Akbas EM, Ozcicek F. Evaluation of ovarian reserve tests in women with systemic lupus erythematosus. Am J Reprod Immunol. 2014;72(1):85–8.

    CAS  PubMed  Google Scholar 

  9. Silva CA, Leal MM, Leone C, et al. Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus. 2002;11(7):419–25.

    CAS  PubMed  Google Scholar 

  10. Rygg M, Pistorio A, Ravelli A, et al. A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis. 2012;71(4):511–7.

    PubMed  Google Scholar 

  11. Brunner HI, Bishnoi A, Barron AC, et al. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus. 2006;15(4):198–206.

    CAS  PubMed  Google Scholar 

  12. Huong DL, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 2002;29(12):2571–6.

    CAS  PubMed  Google Scholar 

  13. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford). 2002;41(6):643–50.

    CAS  Google Scholar 

  14. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005;52(2):514–21.

    PubMed  Google Scholar 

  15. Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163(3):153–63.

    PubMed  PubMed Central  Google Scholar 

  16. Saavedra MA, Miranda-Hernandez D, Sanchez A, et al. Pregnancy outcomes in women with childhood-onset and adult-onset systemic lupus erythematosus: a comparative study. Rheumatol Int. 2016;36(10):1431–7.

    PubMed  Google Scholar 

  17. Silva CA, Hilario MO, Febronio MV, et al. Pregnancy outcome in juvenile systemic lupus erythematosus: a Brazilian multicenter cohort study. J Rheumatol. 2008;35(7):1414–8.

    PubMed  Google Scholar 

  18. Webster WS, Freeman JA. Prescription drugs and pregnancy. Expert Opin Pharmacother. 2003;4(6):949–61.

    PubMed  Google Scholar 

  19. Henderson E, Mackillop L. Prescribing in pregnancy and during breast feeding: using principles in clinical practice. Postgrad Med J. 1027;2011(87):349–54.

    Google Scholar 

  20. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin N Am. 2013;60(1):275–94.

    Google Scholar 

  21. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003;327(7411):368.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case–control study. BMJ. 2001;322(7281):266–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Nakhai-Pour HR, Broy P, Sheehy O, Berard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011;183(15):1713–20.

    PubMed  PubMed Central  Google Scholar 

  24. Edwards DR, Aldridge T, Baird DD, Funk MJ, Savitz DA, Hartmann KE. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol. 2012;120(1):113–22.

    CAS  PubMed  Google Scholar 

  25. Daniel S, Koren G, Lunenfeld E, Bilenko N, Ratzon R, Levy A. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions. CMAJ. 2014;186(5):E177–82.

    PubMed  PubMed Central  Google Scholar 

  26. Ofori B, Oraichi D, Blais L, Rey E, Berard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case–control study. Birth Defects Res B Dev Reprod Toxicol. 2006;77(4):268–79.

    CAS  PubMed  Google Scholar 

  27. van Gelder MM, Roeleveld N, Nordeng H. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. PLoS One. 2011;6(7):e22174.

    PubMed  PubMed Central  Google Scholar 

  28. Daniel S, Matok I, Gorodischer R, et al. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. J Rheumatol. 2012;39(11):2163–9.

    CAS  PubMed  Google Scholar 

  29. Nezvalova-Henriksen K, Spigset O, Nordeng H. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study. BJOG. 2013;120(8):948–59.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40(5):824–9.

    CAS  PubMed  Google Scholar 

  31. Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics. 2001;107(3):519–23.

    CAS  PubMed  Google Scholar 

  32. Cuzzolin L, Dal Cere M, Fanos V. NSAID-induced nephrotoxicity from the fetus to the child. Drug Saf. 2001;24(1):9–18.

    CAS  PubMed  Google Scholar 

  33. Townsend RJ, Benedetti TJ, Erickson SH, et al. Excretion of ibuprofen into breast milk. Am J Obstet Gynecol. 1984;149(2):184–6.

    CAS  PubMed  Google Scholar 

  34. Lebedevs TH, Wojnar-Horton RE, Yapp P, et al. Excretion of indomethacin in breast milk. Br J Clin Pharmacol. 1991;32(6):751–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Voltaren package insert.

  36. Jamali F, Stevens DR. Naproxen excretion in milk and its uptake by the infant. Drug Intell Clin Pharm. 1983;17(12):910–1.

    CAS  PubMed  Google Scholar 

  37. Ostensen M, Matheson I, Laufen H. Piroxicam in breast milk after long-term treatment. Eur J Clin Pharmacol. 1988;35(5):567–9.

    CAS  PubMed  Google Scholar 

  38. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol. 2003;68(1):70–84.

    CAS  PubMed  Google Scholar 

  39. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110e116–120e116.

    Google Scholar 

  40. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet. 1994;343(8898):619–29.

    Google Scholar 

  41. Schramm AM, Clowse ME. Aspirin for prevention of preeclampsia in lupus pregnancy. Autoimmune Dis. 2014;2014:920467.

    PubMed  PubMed Central  Google Scholar 

  42. Stuart MJ, Gross SJ, Elrad H, Graeber JE. Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med. 1982;307(15):909–12.

    CAS  PubMed  Google Scholar 

  43. Sibai BM, Caritis SN, Thom E, Shaw K, McNellis D. Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. Am J Obstet Gynecol. 1995;172(5):1553–7.

    CAS  PubMed  Google Scholar 

  44. Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med. 1989;321(6):357–62.

    CAS  PubMed  Google Scholar 

  45. Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW. Transfer of low dose aspirin into human milk. J Hum Lancet. 2017;33(2):296–9.

    Google Scholar 

  46. Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. Clin Pediatr (Phila). 1981;20(1):53–4.

    CAS  PubMed  Google Scholar 

  47. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol. 1995;173(1):254–62.

    CAS  PubMed  Google Scholar 

  48. Bonanno C, Wapner RJ. Antenatal corticosteroid treatment: what’s happened since Drs Liggins and Howie? Am J Obstet Gynecol. 2009;200(4):448–57.

    CAS  PubMed  Google Scholar 

  49. Benediktsson R, Calder AA, Edwards CR, Seckl JR. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf). 1997;46(2):161–6.

    CAS  Google Scholar 

  50. Burton PJ, Waddell BJ. Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Biol Reprod. 1999;60(2):234–40.

    CAS  PubMed  Google Scholar 

  51. Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case–control study. Teratology. 1998;58(1):2–5.

    CAS  PubMed  Google Scholar 

  52. Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol. 2003;67(12):968–70.

    CAS  PubMed  Google Scholar 

  53. Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796–804.

    PubMed  PubMed Central  Google Scholar 

  54. Bay Bjorn AM, Ehrenstein V, Hundborg HH, Nohr EA, Sorensen HT, Norgaard M. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther. 2014;21(2):73–80.

    PubMed  Google Scholar 

  55. Yildirim Y, Tinar S, Oner RS, Kaya B, Toz E. Gestational diabetes mellitus in patients receiving long-term corticosteroid therapy during pregnancy. J Perinat Med. 2006;34(4):280–4.

    CAS  PubMed  Google Scholar 

  56. Leung YP, Kaplan GG, Coward S, et al. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. J Crohns Colitis. 2015;9(3):223–30.

    PubMed  Google Scholar 

  57. Fisher JE, Smith RS, Lagrandeur R, Lorenz RP. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol. 1997;90(6):880–3.

    CAS  PubMed  Google Scholar 

  58. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992;166(5):1318–23.

    CAS  PubMed  Google Scholar 

  59. Katz FH, Duncan BR. Letter: entry of prednisone into human milk. N Engl J Med. 1975;293(22):1154.

    CAS  PubMed  Google Scholar 

  60. Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ Jr. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther. 1993;53(3):324–8.

    CAS  PubMed  Google Scholar 

  61. Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr. 1985;106(6):1008–11.

    CAS  PubMed  Google Scholar 

  62. Cooper SD, Felkins K, Baker TE, Hale TW. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. J Hum Lancet. 2015;31(2):237–9.

    Google Scholar 

  63. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003;48(11):3207–11.

    CAS  PubMed  Google Scholar 

  64. Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet. 2001;358(9284):813–4.

    CAS  PubMed  Google Scholar 

  65. Law I, Ilett KF, Hackett LP, et al. Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers. Br J Clin Pharmacol. 2008;65(5):674–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Matz GJ, Naunton RF. Ototoxicity of chloroquine. Arch Otolaryngol. 1968;88(4):370–2.

    CAS  PubMed  Google Scholar 

  67. Villegas L, McGready R, Htway M, et al. Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. Trop Med Int Health. 2007;12(2):209–18.

    CAS  PubMed  Google Scholar 

  68. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1):76–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640–7.

    PubMed  Google Scholar 

  70. Koh JH, Ko HS, Kwok SK, Ju JH, Park SH. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus. 2015;24(2):210–7.

    CAS  PubMed  Google Scholar 

  71. Kroese SJ, de Hair MJH, Limper M, et al. Hydroxychloroquine use in lupus patients during pregnancy is associated with longer pregnancy duration in preterm births. J Immunol Res. 2017;2017:2810202.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev. 2005;4(2):111–5.

    CAS  PubMed  Google Scholar 

  73. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65(5):240–61.

    CAS  PubMed  Google Scholar 

  74. Norgard B, Pedersen L, Christensen LA, Sorensen HT. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007;102(7):1406–13.

    PubMed  Google Scholar 

  75. Shim L, Eslick GD, Simring AA, Murray H, Weltman MD. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis. 2011;5(3):234–8.

    PubMed  Google Scholar 

  76. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124(1):9–17.

    CAS  PubMed  Google Scholar 

  77. Langagergaard V, Pedersen L, Gislum M, Norgard B, Sorensen HT. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther. 2007;25(1):73–81.

    CAS  PubMed  Google Scholar 

  78. Sau A, Clarke S, Bass J, Kaiser A, Marinaki A, Nelson-Piercy C. Azathioprine and breastfeeding: is it safe? BJOG. 2007;114(4):498–501.

    CAS  PubMed  Google Scholar 

  79. Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol. 2006;62(4):453–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008;28(10):1209–13.

    CAS  PubMed  Google Scholar 

  81. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71(8):1051–5.

    CAS  PubMed  Google Scholar 

  82. Paziana K, Del Monaco M, Cardonick E, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279–94.

    CAS  PubMed  Google Scholar 

  83. Giudice PL, Dubourg L, Hadj-Aissa A, et al. Renal function of children exposed to cyclosporin in utero. Nephrol Dial Transplant. 2000;15(10):1575–9.

    CAS  PubMed  Google Scholar 

  84. Nulman I, Sgro M, Barrera M, Chitayat D, Cairney J, Koren G. Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant. Paediatr Drugs. 2010;12(2):113–22.

    PubMed  Google Scholar 

  85. Thomas AG, Burrows L, Knight R, Panico M, Lapinski R, Lockwood CJ. The effect of pregnancy on cyclosporine levels in renal allograft patients. Obstet Gynecol. 1997;90(6):916–9.

    CAS  PubMed  Google Scholar 

  86. Moretti ME, Sgro M, Johnson DW, et al. Cyclosporine excretion into breast milk. Transplantation. 2003;75(12):2144–6.

    CAS  PubMed  Google Scholar 

  87. Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000;70(12):1718–21.

    CAS  PubMed  Google Scholar 

  88. Nevers W, Pupco A, Koren G, Bozzo P. Safety of tacrolimus in pregnancy. Can Fam Physician. 2014;60(10):905–6.

    PubMed  PubMed Central  Google Scholar 

  89. Webster P, Wardle A, Bramham K, Webster L, Nelson-Piercy C, Lightstone L. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus. 2014;23(11):1192–6.

    CAS  PubMed  Google Scholar 

  90. Bramham K, Chusney G, Lee J, Lightstone L, Nelson-Piercy C. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol. 2013;8(4):563–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet. 2015;4(2):42–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A(6):1241–8.

    PubMed  Google Scholar 

  93. Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A. 2008;146A(1):1–7.

    PubMed  Google Scholar 

  94. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82(12):1698–702.

    CAS  PubMed  Google Scholar 

  95. Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A(3):588–96.

    PubMed  Google Scholar 

  96. Al Maimouni H, Gladman DD, Ibanez D, Urowitz MB. Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes. Arthritis Care Res (Hoboken). 2014;66(12):1905–9.

    CAS  PubMed  Google Scholar 

  97. Fischer-Betz R, Specker C, Brinks R, Aringer M, Schneider M. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford). 2013;52(6):1070–6.

    CAS  Google Scholar 

  98. Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101–10.

    CAS  PubMed  Google Scholar 

  99. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology. 1998;57(2):51–5.

    CAS  PubMed  Google Scholar 

  100. Lewden B, Vial T, Elefant E, et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol. 2004;31(12):2360–5.

    CAS  PubMed  Google Scholar 

  101. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68(7):1086–93.

    CAS  PubMed  Google Scholar 

  102. Thorne JC, Nadarajah T, Moretti M, Ito S. Methotrexate use in a breastfeeding patient with rheumatoid arthritis. J Rheumatol. 2014;41(11):2332.

    PubMed  Google Scholar 

  103. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776–89.

    Google Scholar 

  104. Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet. 1999;86(3):237–41.

    CAS  PubMed  Google Scholar 

  105. Kirshon B, Wasserstrum N, Willis R, Herman GE, McCabe ER. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol. 1988;72(3 Pt 2):462–4.

    CAS  PubMed  Google Scholar 

  106. Paladini D, Vassallo M, D’Armiento MR, Cianciaruso B, Martinelli P. Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol. 2004;70(2):99–100.

    CAS  PubMed  Google Scholar 

  107. Vaux KK, Kahole NC, Jones KL. Cyclophosphamide, methotrexate, and cytarabine embropathy: is apoptosis the common pathway? Birth Defects Res A Clin Mol Teratol. 2003;67(6):403–8.

    CAS  PubMed  Google Scholar 

  108. Zemlickis D, Lishner M, Erlich R, Koren G. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen. 1993;13(3):139–43.

    CAS  PubMed  Google Scholar 

  109. Kart Koseoglu H, Yucel AE, Kunefeci G, Ozdemir FN, Duran H. Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus. 2001;10(11):818–20.

    CAS  PubMed  Google Scholar 

  110. Hardin JA. Cyclophosphamide treatment of lymphoma during third trimester of pregnancy. Obstet Gynecol. 1972;39(6):850–1.

    CAS  PubMed  Google Scholar 

  111. Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999;17(3):855–61.

    CAS  PubMed  Google Scholar 

  112. Durodola JI. Administration of cyclophosphamide during late pregnancy and early lactation: a case report. J Natl Med Assoc. 1979;71(2):165–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  113. Perricone R, De Carolis C, Kroegler B, et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology (Oxford). 2008;47(5):646–51.

    CAS  Google Scholar 

  114. Clark AL, Gall SA. Clinical uses of intravenous immunoglobulin in pregnancy. Am J Obstet Gynecol. 1997;176(1 Pt 1):241–53.

    CAS  PubMed  Google Scholar 

  115. Kaaja R, Julkunen H, Ammala P, Teppo AM, Kurki P. Congenital heart block: successful prophylactic treatment with intravenous gamma globulin and corticosteroid therapy. Am J Obstet Gynecol. 1991;165(5 Pt 1):1333–4.

    CAS  PubMed  Google Scholar 

  116. David AL, Ataullah I, Yates R, Sullivan I, Charles P, Williams D. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin. Obstet Gynecol. 2010;116(Suppl 2):543–7.

    PubMed  Google Scholar 

  117. Gordon C, Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Lupus. 1998;7(7):429–33.

    CAS  PubMed  Google Scholar 

  118. Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A. Intravenous immunoglobulins and antiphospholipid syndrome: how, when and why? A review of the literature. Autoimmun Rev. 2016;15(3):226–35.

    CAS  PubMed  Google Scholar 

  119. Palmeira P, Costa-Carvalho BT, Arslanian C, Pontes GN, Nagao AT, Carneiro-Sampaio MM. Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin. Pediatr Allergy Immunol. 2009;20(6):528–35.

    PubMed  Google Scholar 

  120. Ton E, Tekstra J, Hellmann PM, Nuver-Zwart IH, Bijlsma JW. Safety of rituximab therapy during twins’ pregnancy. Rheumatology (Oxford). 2011;50(4):806–8.

    Google Scholar 

  121. Malek A. Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine. 2003;21(24):3362–4.

    CAS  PubMed  Google Scholar 

  122. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008;2008:271363.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Gasparoni A, Avanzini A, Ravagni Probizer F, Chirico G, Rondini G, Severi F. IgG subclasses compared in maternal and cord serum and breast milk. Arch Dis Child. 1992;67((Spec No 1)):41–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Bragnes Y, Boshuizen R, de Vries A, Lexberg A, Ostensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology (Oxford). 2017;56(6):1047–8.

    CAS  Google Scholar 

  125. Emmi G, Silvestri E, Squatrito D, et al. Favorable pregnancy outcome in a patient with systemic lupus erythematosus treated with belimumab: a confirmation report. Semin Arthritis Rheum. 2016;45(6):e26–7.

    PubMed  Google Scholar 

  126. Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report. Semin Arthritis Rheum. 2014;44(2):195–7.

    PubMed  Google Scholar 

  127. Bitter H, Bendvold AN, Ostensen ME. Lymphocyte changes and vaccination response in a child exposed to belimumab during pregnancy. Ann Rheum Dis. 2018. https://doi.org/10.1136/annrheumdis-2018-213004.

    Article  PubMed  Google Scholar 

  128. Auyeung-Kim DJ, Devalaraja MN, Migone TS, Cai W, Chellman GJ. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod Toxicol. 2009;28(4):443–55.

    CAS  PubMed  Google Scholar 

  129. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012;60(2):444–50.

    CAS  PubMed  Google Scholar 

  130. Nadeem S, Hashmat S, Defreitas MJ, et al. Renin angiotensin system blocker fetopathy: a midwest pediatric nephrology consortium report. J Pediatr. 2015;167(4):881–5.

    PubMed  Google Scholar 

  131. Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int. 2012;2012:658310.

    PubMed  Google Scholar 

  132. Bateman BT, Patorno E, Desai RJ, et al. Angiotensin-converting enzyme inhibitors and the risk of congenital malformations. Obstet Gynecol. 2017;129(1):174–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443–51.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bonnie L. Bermas.

Ethics declarations

Conflict of interest

Drs Bitencourt and Bermas report no conflicts of interest.

Funding

No funding was received for the preparation of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bitencourt, N., Bermas, B.L. Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding. Pediatr Drugs 20, 511–521 (2018). https://doi.org/10.1007/s40272-018-0312-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-018-0312-2

Navigation